Literature DB >> 10828869

Introduction of the oncological pediatric risk of mortality score (O-PRISM) for ICU support following stem cell transplantation in children.

D T Schneider1, P Lemburg, I Sprock, R Heying, U Göbel, W Nürnberger.   

Abstract

Prognostic scoring systems based on physiological parameters have been established in order to predict the outcome of ICU patients. It has been demonstrated that the predictive value of these scores is limited in patients following hematopoietic stem cell transplantation (HSCT). Therefore, we evaluated patients from the Düsseldorf pediatric stem cell transplantation center with regard to predisposing factors and prognostic variables for ICU treatment and outcome. Between January 1989 and December 1998, 180 HSCT have been performed. The clinical, laboratory and HSCT-related parameters such as conditioning treatment, engraftment, GVHD, infections and HSCT toxicity were prospectively recorded and retrospectively analyzed. Established pediatric scoring systems (PRISM, TISS, P-TISS) were applied. Twenty-eight patients required intensive care (16 male, 12 female, median age: 10.9 years (range: 0.4 to 18.9 years), five autologous, 13 allogeneic-related and 10 unrelated transplanted patients). Ventilator-dependent respiratory failure was the most frequent cause of admission to the ICU (n = 23). Fourteen of 28 patients were discharged from ICU, and six of 28 patients achieved a long-term survival (110 to 396 weeks). At admission to the ICU, impaired cardiovascular status, high CRP levels and presence of macroscopic bleeding were each associated with fatal outcome (P < 0.05). The Pediatric Risk of Mortality (PRISM) score was not prognostically significant at the 0.05 level. Long-term survival after discharge from the ICU correlated with HSCT-related parameters such as the type of transplant and severity of GVHD (P = 0.002). By introduction of HSCT related parameters such as severity of GVHD (grade 2: 2 points; grade >2: 4 points), CRP-level (>10 mg/dl: 4 points), and presence of macroscopic bleeding (4 points) into the PRISM score a new oncological PRISM ('O-PRISM') score was established. This score significantly correlated with the risk of mortality in the ICU (P = 0.01). In conclusion, the new O-PRISM score accurately characterizes the clinical situation of children requiring ICU treatment following HSCT. It distinguishes more appropriately between success and failure of ICU treatment following HSCT than the standard prognostic scores. It needs to be evaluated in future prospective studies of critically ill children after HSCT. Bone Marrow Transplantation (2000).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828869     DOI: 10.1038/sj.bmt.1702403

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  Comment on "impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with haematological malignancies" by Vandijck et al.

Authors:  Sascha Meyer; Ludwig Gortner; Sven Gottschling
Journal:  Intensive Care Med       Date:  2008-07-18       Impact factor: 17.440

2.  Pediatric Hematopoietic Cell Transplant Patients Who Survive Critical Illness Frequently Have Significant but Recoverable Decline in Functional Status.

Authors:  Matt S Zinter; Richard Holubkov; Martina A Steurer; Christopher C Dvorak; Christine N Duncan; Anil Sapru; Robert F Tamburro; Patrick S McQuillen; Murray M Pollack
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-08       Impact factor: 5.742

3.  Risk factors associated with pediatric intensive care unit admission and mortality after pediatric stem cell transplant: possible role of renal involvement.

Authors:  Nabil E Hassan; Aly S Mageed; Dominic J Sanfilippo; Dianne Reischman; Ulrich A Duffner; Surender Rajasekaran
Journal:  World J Pediatr       Date:  2012-12-29       Impact factor: 2.764

4.  Outcome and prognostic factors seen in pediatric oncology patients admitted in PICU of a developing country.

Authors:  Nida Akhtar; Zehra Fadoo; Sukaina Panju; Anwarul Haque
Journal:  Indian J Pediatr       Date:  2011-03-25       Impact factor: 1.967

5.  Assessing the risk of mortality in paediatric cancer patients admitted to the paediatric intensive care unit: a novel risk score?

Authors:  Sascha Meyer; Sven Gottschling; Tamir Biran; Thomas Georg; Karim Ehlayil; Norbert Graf; Ludwig Gortner
Journal:  Eur J Pediatr       Date:  2005-05-24       Impact factor: 3.183

6.  Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

Authors:  Andrew Jarnicki; Tracy Putoczki; Matthias Ernst
Journal:  Cell Div       Date:  2010-05-17       Impact factor: 5.130

7.  The critically-ill pediatric hemato-oncology patient: epidemiology, management, and strategy of transfer to the pediatric intensive care unit.

Authors:  Pierre Demaret; Geraldine Pettersen; Philippe Hubert; Pierre Teira; Guillaume Emeriaud
Journal:  Ann Intensive Care       Date:  2012-06-12       Impact factor: 6.925

8.  Pediatric Intensive Care Unit admission criteria for haemato-oncological patients: a basis for clinical guidelines implementation.

Authors:  Marco Piastra; Giuliana Fognani; Alessia Franceschi
Journal:  Pediatr Rep       Date:  2011-06-16

9.  Epidemiology and Outcome of Critically Ill Pediatric Cancer and Hematopoietic Stem Cell Transplant Patients Requiring Continuous Renal Replacement Therapy: A Retrospective Nationwide Cohort Study.

Authors:  Paulien A M A Raymakers-Janssen; Marc R Lilien; Dick Tibboel; Martin C J Kneyber; Sandra Dijkstra; Job B M van Woensel; Joris Lemson; Karlien Cransberg; Marry M van den Heuvel-Eibrink; Roelie M Wösten-van Asperen
Journal:  Crit Care Med       Date:  2019-11       Impact factor: 7.598

10.  G-CSF mobilised granulocyte transfusions in 32 paediatric patients with neutropenic sepsis.

Authors:  Lorenz Grigull; Nicole Pulver; Lilia Goudeva; Karl-Walter Sykora; Christin Linderkamp; Andreas Beilken; Kathrin Seidemann; Hansjörg Schmid; Karl Welte; Hans-Gert Heuft
Journal:  Support Care Cancer       Date:  2006-04-19       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.